Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
27 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/27/3088653/0/en/AskBio-Announces-Publication-of-Complete-Results-of-Phase-1b-Trial-of-AB-1005-Gene-Therapy-in-Participants-with-Parkinson-s-Disease-in-Movement-Disorders.html
25 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/belief-biomed-to-collaborate-with-askbio-to-explore-the-potential-of-new-gene-therapies-302258260.html
12 Jul 2024
// PHARMACEUTICAL-TECHNOLOGY
https://www.pharmaceutical-technology.com/news/fda-askbio-ab-1005-pd/
27 Jun 2024
// PHARMABIZ
09 Apr 2024
// CONTRACTPHARMA
https://www.contractpharma.com/contents/view_breaking-news/2024-04-09/askbio-names-dr-mansuo-shannon-as-chief-scientific-officer/
13 Feb 2024
// PRESS RELEASE
https://www.bayer.com/media/en-us/first-patient-randomized-in-askbio-phase-ii-gene-therapy-trial-for-congestive-heart-failure/
Details:
AB-1005 is an investigational gene therapy based on AAV2 containing the GDNF transgene. It is under phase 1 clinical development for the treatment of Parkinson's disease.
Lead Product(s): AB-1005
Therapeutic Area: Neurology Brand Name: AB-1005
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 07, 2024
FDA grants fast track designation to AskBio’s AB-1005 for PD
Details : AB-1005 is an investigational gene therapy based on AAV2 containing the GDNF transgene. It is under phase 1 clinical development for the treatment of Parkinson's disease.
Product Name : AB-1005
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 07, 2024
Details:
AB-1005 is an investigational gene therapy based on AAV2 containing the GDNF transgene. It is under phase 1 clinical development for the treatment of Parkinson's disease.
Lead Product(s): AB-1005
Therapeutic Area: Rare Diseases and Disorders Brand Name: AB-1005
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 27, 2024
Lead Product(s) : AB-1005
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AskBio Begins Patient Recruitment for AB-1005 in Phase 2 Parkinson’s Trial
Details : AB-1005 is an investigational gene therapy based on AAV2 containing the GDNF transgene. It is under phase 1 clinical development for the treatment of Parkinson's disease.
Product Name : AB-1005
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 27, 2024
Details:
NAN-101 (AB-1002) is a gene therapy under investigation, currently undergoing phase 2 clinical trials for the treatment of congestive heart failure.
Lead Product(s): NAN-101
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: NAN-101
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Bayer AG
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 18, 2024
Lead Product(s) : NAN-101
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
AskBio Gets FDA Fast Track Designation for AB-1002 Gene Therapy Program in Heart Failure
Details : NAN-101 (AB-1002) is a gene therapy under investigation, currently undergoing phase 2 clinical trials for the treatment of congestive heart failure.
Product Name : NAN-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 18, 2024
Details:
AB-1005 (AAV2-GDNF) is an investigational gene therapy based on AAV2 containing the human glial cell line-derived neurotrophic factor (GDNF) transgene, being investigated for Parkinson’s disease.
Lead Product(s): AB-1005
Therapeutic Area: Neurology Brand Name: AB-1005
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Bayer AG
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 16, 2024
Askbio Presents 18-Month Phase Ib Trial Results of AB-1005 Gene Therapy for Parkinson’s
Details : AB-1005 (AAV2-GDNF) is an investigational gene therapy based on AAV2 containing the human glial cell line-derived neurotrophic factor (GDNF) transgene, being investigated for Parkinson’s disease.
Product Name : AB-1005
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 16, 2024
Details:
AB-1005 is an investigational gene therapy based on AAV2 containing the human GDNF transgene. It is under Phase 1 clinical development for treating Parkinson's disease.
Lead Product(s): AB-1005
Therapeutic Area: Neurology Brand Name: AB-1005
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Bayer AG
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2024
AskBio Phase Ib Trial Of Ab-1005 Gene Therapy in Parkinson’s Disease Meets Endpoint
Details : AB-1005 is an investigational gene therapy based on AAV2 containing the human GDNF transgene. It is under Phase 1 clinical development for treating Parkinson's disease.
Product Name : AB-1005
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 01, 2024
Details:
AB-1002 (NAN-101) is an investigational gene therapy, which is currently under phase 2 clinical development for the treatment of congestive heart failure.
Lead Product(s): NAN-101
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: NAN-101
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Bayer AG
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 16, 2024
Lead Product(s) : NAN-101
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Heart Failure
Details : AB-1002 (NAN-101) is an investigational gene therapy, which is currently under phase 2 clinical development for the treatment of congestive heart failure.
Product Name : NAN-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 16, 2024
Details:
AB-1005 is an investigational gene therapy based on adeno-associated viral vector serotype 2 (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene. It is under phase 1 clinical development for the treatment of Parkinson's disease.
Lead Product(s): AB-1005
Therapeutic Area: Rare Diseases and Disorders Brand Name: AB-1005
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2023
Lead Product(s) : AB-1005
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AskBio announces First Patient Randomized in Phase 1 Trial of AB-1005
Details : AB-1005 is an investigational gene therapy based on adeno-associated viral vector serotype 2 (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene. It is under phase 1 clinical development for the treatment of Parkinson...
Product Name : AB-1005
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 17, 2023
Details:
AskBio will combine its synthetic DNA and gene editing nucleases with ReCode's selective organ targeting LNP technology to potentially create an all-in-one solution that enables full gene insertion by delivering with precision both the gene editing tool and DNA.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: ReCode Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : ReCode Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : AskBio will combine its synthetic DNA and gene editing nucleases with ReCode's selective organ targeting LNP technology to potentially create an all-in-one solution that enables full gene insertion by delivering with precision both the gene editing tool ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 01, 2023
Details:
AB-1005 is an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of mild to moderate parkinson’s disease.
Lead Product(s): AB-1005
Therapeutic Area: Neurology Brand Name: AB-1005
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2023
Details : AB-1005 is an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of mild to moderate parkinson’s disease.
Product Name : AB-1005
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 29, 2023
Details:
AB-1003 (also known as LION-101) is a novel investigational recombinant adeno-associated virus based gene therapy currently being developed as a one-time intravenous infusion for the treatment of patients with LGMD type 2I/R9.
Lead Product(s): AB-1003
Therapeutic Area: Genetic Disease Brand Name: AB-1003
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 08, 2023
Lead Product(s) : AB-1003
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB-1003 (also known as LION-101) is a novel investigational recombinant adeno-associated virus based gene therapy currently being developed as a one-time intravenous infusion for the treatment of patients with LGMD type 2I/R9.
Product Name : AB-1003
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 08, 2023
ABOUT THIS PAGE
AskBio is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV) bulk offered by AskBio